Immix Biopharma
IMMX8.6902.00% ( +0.170 )
Immix Biopharma (IMMX)
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidos...
- Open
- 8.630
- High
- 9.390
- Low
- 8.580
- Prev. Close
- 8.520
- Volume
- 1.99M
- Turnover
- 17.71M
- Avg Price
- 8.900
- Bid/Ask Ratio
- --
- Amplitude
- 9.51%
- 52wk High
- 12.140
- Volume Ratio
- 0.81
- Turnover Ratio
- 3.51%
Immix Biopharma Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$19.91129.11%
Forecast & RatingStrong buy
7analysts
- Strong buy57.14%
- Buy42.86%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 22 at 07:12 AM
Immix Biopharma (NASDAQ:IMMX) Coverage Initiated at Needham & Company LLC
- PUBT · Jul 20 at 05:06 AM
Immix Biopharma terminates Richard Graydon employment
- PUBT · Jul 3 at 10:50 AM
Immix Biopharma posts corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis
- benzinga_article · Jun 18 at 12:38 PM
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
- TradingView · Jun 18 at 08:20 AM
Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% Upside
- benzinga_article · Jun 18 at 06:45 AM
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
